Lemonaid Health AI Visibility Market Strategy Report - ED Treatment Pills

Answer Capsule

Lemonaid Health holds 30.41% valid recommendation coverage in the October 2026 ED Treatment Pills benchmark, ranking fourth of ten tracked brands. The brand shows strong positive framing at 0.9074 net sentiment, the highest among tracked brands, but converts presence into top-three recommendations at only 17.91%, well behind category leaders Hims (48.65%) and Ro (42.23%). The clearest win is sentiment quality and a significant September-to-October recovery from 21.3% to 30.4% coverage. The clearest gap is first-position recommendation power, where Lemonaid Health registers only 1.35% rank-one rate against Hims at 28.38%. The biggest opportunity sits in converting its strong positive framing into higher placement within AI-generated shortlists.

Who This Report Is For

This report is for Lemonaid Health's marketing, growth, and brand strategy teams, and for category analysts tracking how telehealth brands compete for recommendation-stage visibility in AI-led discovery for ED treatment pills.

Report Card

Executive Summary

Lemonaid Health enters October 2026 with 30.41% valid recommendation coverage, placing fourth among ten tracked ED treatment brands. The brand's raw mention presence rate of 36.49% shows it appears in more than a third of qualified AI responses, but its valid recommendation coverage of 30.41% and top-three rate of 17.91% reveal a meaningful gap between being mentioned and being recommended prominently.

The sentiment picture is the strongest signal in the dataset. Lemonaid Health records a net sentiment score of 0.9074, the highest among all tracked brands, with 98 positive mentions, 10 neutral mentions, and zero negative mentions across 108 total mentions. This indicates that when AI systems do surface Lemonaid Health, the framing is overwhelmingly positive.

The September-to-October recovery was significant. Coverage rose from 21.3% to 30.4%, a 9.1 point increase classified as beyond normal variation. Against the July 2026 baseline of 25.5%, the brand has gained 4.9 points, placing it among the category's positive movers alongside GoodRx Care and Hims.

The strongest platform signal comes from AI Overviews, where Lemonaid Health achieves 50.0% valid recommendation coverage and a 31.4% top-three rate. The brand also performs well on AI Mode with 32.1% coverage. However, the brand registers zero presence on Perplexity and ChatGPT in the qualified dataset, and its Copilot coverage is minimal at 7.7%.

The clearest gap is first-position recommendation power. Lemonaid Health's rank-one rate of 1.35% means it is the single first recommended option in only 4 of 296 qualified observations. By comparison, Hims achieves 28.38% and GoodRx Care 15.88%. The brand is being recommended, but rarely as the default answer.

The strongest cluster is Brand Recommendation (C01), the only cluster with qualified data in October 2026. The pricing and value cluster (C03) and multi-brand comparison cluster (C02) carry no qualified observations, meaning the benchmark cannot yet measure how Lemonaid Health performs on cost-focused or head-to-head comparison prompts.

What Lemonaid Health Is Winning

Questions This Section Answers

• Where does Lemonaid Health rank strongest in sentiment and platform coverage?
• What role does lemonaidhealth.com play in the AI citation layer for ED treatment recommendations?

Lemonaid Health holds the highest net sentiment score in the category at 0.9074, ahead of GoodRx Care (0.8357), Ro (0.8074), and Hims (0.8029). This reflects a framing environment where AI systems consistently present the brand positively when it appears.

The brand recorded a significant September-to-October recovery, rising 9.1 points from 21.3% to 30.4% valid recommendation coverage. This places Lemonaid Health among the category's positive movers for the month.

AI Overviews is the strongest platform for Lemonaid Health, where the brand achieves 50.0% valid recommendation coverage and 31.4% top-three rate. The brand also holds 32.1% coverage on AI Mode. These two Google-integrated surfaces account for the majority of the brand's recommendation presence.

The brand's own domain, lemonaidhealth.com, appears in the top 10 cited domains for October 2026 with 112 citations (1.7% share), cited across Gemini, AI Mode, AI Overviews, and Perplexity. This indicates the brand's owned content is part of the public evidence layer that AI systems retrieve.

Where Lemonaid Health Has the Clearest AI Visibility Gaps

Questions This Section Answers

• How large is the gap between Lemonaid Health's top-three placements and rank-one recommendations?
• Which AI platforms fail to recommend Lemonaid Health at all?
• Why does Lemonaid Health's mention presence not fully convert into valid recommendation coverage?

The most significant gap is first-position recommendation conversion. Lemonaid Health achieves a 17.91% top-three rate and a 1.35% rank-one rate, meaning the brand appears in the top three in 53 of 296 observations but as the first recommendation in only 4. Hims, by contrast, achieves 144 top-three placements and 84 rank-one placements. The gap between being shortlisted and being the default answer is where Lemonaid Health loses the most ground.

Platform absence is a second clear gap. Lemonaid Health registers zero mentions on Perplexity and zero mentions on ChatGPT in the qualified October 2026 dataset. On Copilot, the brand achieves only 7.7% valid recommendation coverage. These three platforms represent surfaces where the brand is effectively invisible at the recommendation stage.

The brand's average recommended rank of 3.2414 places it behind Hims (2.0417), Ro (2.4702), and GoodRx Care (2.6596). Even when Lemonaid Health is recommended, it typically appears third rather than first or second, reducing its prominence in AI-generated shortlists.

Competitive displacement is visible in the data. When Lemonaid Health is absent from a recommendation, the position is typically filled by Hims, Ro, or GoodRx Care. The three leaders collectively hold 60.8%, 55.1%, and 51.0% valid recommendation coverage respectively, leaving limited shortlist space for fourth-place brands.

The brand's presence-to-recommendation conversion rate shows room for improvement. With a 36.49% raw mention presence rate but only 30.41% valid recommendation coverage, approximately 6.1 percentage points of presence do not convert to recommendation credit. This suggests the brand is sometimes mentioned as context or comparison rather than as a recommended option.

Biggest Opportunity

The clearest path from reference to recommendation for Lemonaid Health is converting its strong positive framing into higher placement within AI-generated shortlists. The brand already achieves the highest net sentiment in the category at 0.9074, meaning AI systems frame Lemonaid Health positively when it appears. The opportunity is to move from being positively mentioned to being the first or second recommended option.

This opportunity is concentrated in the Brand Recommendation cluster (C01), the only cluster with qualified data. Within this cluster, the brand's 17.91% top-three rate and 1.35% rank-one rate show substantial headroom. If Lemonaid Health could convert even half of its current top-three placements into rank-one positions, its recommendation prominence would shift materially.

The platform-specific opportunity is most acute on AI Overviews and AI Mode, where the brand already performs well. Strengthening the citation and evidence layer that feeds these surfaces could reinforce the brand's position. The brand's own domain already appears in the top 10 cited domains, providing a foundation to build on.

Competitive Landscape

Questions This Section Answers

• Which ED treatment brands lead Lemonaid Health in recommendation power?
• How does Lemonaid Health's sentiment compare with its top-three and rank-one rates?

Hims holds dominant recommendation power in the ED Treatment Pills category with 60.8% valid recommendation coverage and a 28.38% rank-one rate. Ro and GoodRx Care form a strong challenger tier, while Lemonaid Health sits in a fourth position with strong sentiment but weaker placement conversion.

Average recommended rank covers rank-eligible recommendations only.

Lemonaid Health ranks fourth by top-three rate, behind Hims, Ro, and GoodRx Care, but ahead of plushcare, BlueChew, and the remaining tracked brands. The brand's rank-one rate of 1.35% places it sixth, behind Rex MD and ahead of BlueChew, Blink Health, K Health, and Optum. The table shows that Lemonaid Health has established itself in the recommendation tier but has not yet converted that position into first-choice status at scale.

AI Response Inconsistency Alerts

Questions This Section Answers

• Which factual conflicts about Lemonaid Health appear across AI platforms?
• What sources are driving inconsistent claims about Lemonaid Health's ownership and insurance?

AI platforms provided conflicting information about Lemonaid Health in 2 critical or high-severity factual inconsistencies detected across 2 AI platforms. These conflicts involve ownership claims and insurance acceptance, both surfaced when users asked the question "Is Lemonaid Health legit?"

On the topic of ownership, Gemini stated that Lemonaid Health was "acquired by 247id (formerly Truepill) in 2021," while Copilot stated the company is "owned by 23andMe." These claims cannot both be accurate unless one entity is a subsidiary of the other, which neither response states. Copilot cited three source pages in its response: a review on glp-1.reviews, a review on betterresultsbook.com, and a safety newsroom page on formblends.com. The flagged sources include an excerpt from formblends.com stating "23andMe-owned telehealth platform offering GLP-1 weight-loss prescribing" and an excerpt from glp-1.reviews stating "Part of 23andMe, backed by a data-driven health technology company."

On the topic of insurance acceptance, Gemini advised users to "check whether your specific insurance plan covers the consultation," while Copilot stated "no insurance accepted." These positions are contradictory: if no insurance is accepted, checking plan coverage would be irrelevant. Copilot again cited the same three source pages, with flagged excerpts including "No insurance accepted, patients pay full out-of-pocket costs" from glp-1.reviews and "it's not the right choice for anyone who needs therapy, controlled substances, or insurance-covered visits" from betterresultsbook.com.

These inconsistencies suggest that the public evidence layer contains conflicting or outdated information about Lemonaid Health's corporate ownership and insurance policies. The source pages cited by Copilot appear to carry claims that differ from what Gemini surfaces, indicating that AI systems are synthesizing from different or conflicting source material when answering legitimacy-related questions about the brand.

Prompt Evidence

Gemini / Brand Recommendation Prompt: "Is Lemonaid Health legit?" Result: Gemini provided a positive assessment but referenced ownership by 247id (formerly Truepill), a claim that conflicts with other platform responses.

Copilot / Brand Recommendation Prompt: "Is Lemonaid Health legit?" Result: Copilot stated the company is owned by 23andMe and does not accept insurance, citing third-party review sites as sources.

AI Overviews / Brand Recommendation Prompt: "What is the best generic Viagra?" Result: Lemonaid Health appeared in the recommendation set with positive framing, contributing to its 50.0% coverage on this platform.

AI Mode / Brand Recommendation Prompt: "how to get viagra" Result: Lemonaid Health was included among recommended telehealth options, supporting its 32.1% coverage on AI Mode.

What CiteWorks Studio Would Do Next

Phase 1: AI Visibility Market Discovery Audit Map Lemonaid Health's prompt-level visibility across all six AI platforms, identifying which specific questions trigger recommendations and which route to competitors.

Phase 2: Recommendation Readiness Plan Prioritize the Brand Recommendation cluster to close the gap between positive mentions and top-three placements, focusing on prompts where the brand currently ranks third or lower.

Phase 3: Owned Answer Layer Buildout Strengthen lemonaidhealth.com content to clarify ownership, insurance policies, and service differentiators, addressing the source conflicts that produce inconsistent AI responses.

Phase 4: Citation / Authority Layer Development Expand the brand's presence in third-party review sites, health publishers, and comparison pages that AI systems cite, ensuring accurate and consistent information across the public evidence layer.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track coverage, top-three rate, rank-one rate, and sentiment month over month to measure whether placement conversion improves and whether platform gaps close.

Why This Matters

AI presence alone is not enough. Lemonaid Health already achieves the highest sentiment score in the category and appears in more than a third of qualified AI responses, yet it converts that presence into first-position recommendations at only 1.35%. The gap between being mentioned positively and being the default answer is where buyer decisions are shaped.

The next move is targeted correction of the prompt, page, and citation layers. The brand needs to ensure that AI systems retrieve accurate, consistent information about its ownership, insurance policies, and service offerings. It also needs to strengthen its position on platforms where it is currently absent, particularly Perplexity and ChatGPT. Closing these gaps would move Lemonaid Health from a positively framed also-ran to a genuine contender for first-position recommendations in AI-generated shortlists.

Core Metrics

Sentiment Score

Questions This Section Answers

• Why is a high sentiment score not enough to secure first-position recommendations?
• How does Lemonaid Health's sentiment score compare with its top-three and rank-one rates?

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Lemonaid Health in October 2026: (98 × 1 + 10 × 0 + 0 × -1) / 108 = 0.9074

This score matters because unclassified mention counts are misleading. A brand with 108 mentions could appear strong on raw volume, but if those mentions are neutral references or cautionary comparisons, the brand is not actually being recommended. Lemonaid Health's score of 0.9074 indicates that when AI systems mention the brand, the framing is overwhelmingly positive, with zero negative mentions recorded.

Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal in commercial value. Counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, because it distinguishes between being talked about and being recommended.

Lemonaid Health's high sentiment score is a genuine strength, but it must be read alongside the brand's 17.91% top-three rate and 1.35% rank-one rate. Positive framing does not automatically convert to first-position recommendations. The brand is well-regarded when it appears, but it appears less prominently than the category leaders.

Sentiment by Platform

Questions This Section Answers

• Which platforms show the strongest sentiment toward Lemonaid Health?
• Where does Lemonaid Health have no public presence in AI responses?

Methodology

1. This report is a benchmark-based analysis of Lemonaid Health's AI visibility in the ED Treatment Pills category, using data from the LLM Authority Index AI Visibility Market Discovery Index for October 2026.
2. The reporting window is October 2026, with comparison to the July 2026 baseline and September 2026 prior month where available.
3. Six AI platforms were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode. All six registered qualified observations in October 2026.
4. The October 2026 benchmark produced 296 qualified observations after qualification from an initial 800 prompt-surface observations.
5. The competitor universe includes ten tracked brands: Hims, Ro, GoodRx Care, Lemonaid Health, plushcare, BlueChew, Rex MD, Blink Health, K Health, and Optum.
6. The public benchmark reports on one qualified buyer-intent cluster in October 2026: Brand Recommendation (C01). Pricing and value (C03) and multi-brand comparison (C02) clusters carry no qualified observations.
7. Stage 0 extraction retains the query, AI/search surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources.
8. A mention is defined as any appearance of the brand in a qualified AI response, regardless of recommendation status.
9. A valid recommendation is defined as an appearance where the brand is explicitly recommended or shortlisted, excluding neutral references, cautionary mentions, or comparison anchors.
10. Brand-level percentages use the 296 qualified observations as the public denominator, not the raw 800-prompt collection.
11. The benchmark records change but does not establish causation. Movement between months identifies changes worth investigating.
12. Limitations: The public benchmark does not measure market share, revenue attribution, organic search ranking, social media sentiment, or private channels. The pricing and comparison clusters carry no qualified data in October 2026, limiting analysis of cost-focused and head-to-head prompts.

See How AI Is Recommending Your Brand

The public benchmark shows where Lemonaid Health stands in AI-generated recommendations for ED treatment pills. A company-level AI visibility audit maps the prompt, surface, competitor, ranking, sentiment, and evidence-source patterns behind those numbers into a prioritized strategy. It answers which prompts Lemonaid Health should win next, which competitors are taking recommendations when the brand loses, and what evidence would move those outcomes.